PSMF and QPPV Oversight

Introduction

The Qualified Person Responsible for Pharmacovigilance (QPPV) occupies a unique position within the pharmacovigilance system.

Unlike operational functions, the QPPV is not primarily responsible for performing pharmacovigilance activities.

Instead, the QPPV is responsible for maintaining oversight of those activities.

This distinction is important.

A QPPV does not need to process every case.

A QPPV does not need to submit every report.

A QPPV does not need to perform every audit.

However, the QPPV must understand how those activities are organised, governed and controlled.

The Pharmacovigilance System Master File is one of the most important tools available for achieving that oversight.

In mature organisations, the PSMF functions as the operational map of the pharmacovigilance system.

For many QPPVs it becomes the single most valuable governance document within the organisation.

Why QPPVs Need the PSMF

Modern pharmacovigilance systems are increasingly complex.

A typical organisation may include:

• Multiple affiliates
• Outsourced vendors
• Numerous products
• Multiple safety databases
• Several governance committees
• Global and regional operating models

No individual can directly observe every pharmacovigilance activity.

Oversight therefore depends upon structured governance mechanisms.

The PSMF helps the QPPV understand:

• How the system operates
• Who performs activities
• Where risks exist
• How compliance is monitored
• How accountability is maintained

Without a reliable system description, effective oversight becomes significantly more difficult.

The Difference Between Management and Oversight

One of the most common misunderstandings concerns the difference between operational management and oversight.

Operational management focuses on:

• Performing activities
• Delivering outputs
• Managing workloads

Oversight focuses on:

• Monitoring effectiveness
• Identifying risks
• Escalating issues
• Verifying controls

The QPPV operates primarily within the second category.

The PSMF supports this role because it describes:

• Governance structures
• Oversight mechanisms
• Responsibilities
• Escalation pathways

The PSMF as a Governance Map

A useful way to think about the PSMF is as a governance map.

Every major section answers an oversight question.

Viewed this way, the PSMF becomes much more than a regulatory requirement.

It becomes a structured oversight tool.

Understanding System Scope

One of the most important responsibilities of a QPPV is understanding the scope of the pharmacovigilance system.

Questions include:

• Which products are covered?
• Which territories are included?
• Which affiliates participate?
• Which activities are outsourced?

The PSMF provides visibility regarding these boundaries.

This becomes particularly important during:

• Acquisitions
• Divestments
• Organisational restructuring
• New market entry

Without a clear understanding of scope, oversight can quickly become fragmented.

Vendor Oversight

Vendor oversight is one of the most significant challenges facing modern QPPVs.

Activities frequently outsourced include:

• Case processing
• Literature surveillance
• Aggregate reporting
• Medical review
• Database hosting

The PSMF helps the QPPV understand:

• Which vendors exist
• Which activities they perform
• Which oversight mechanisms apply
• Who owns vendor relationships

A well-maintained vendor inventory often provides one of the quickest ways to assess organisational complexity.

Using the PSMF to Identify Risk

Experienced QPPVs rarely view the PSMF as a static document.

Instead, they use it to identify areas of potential risk.

Examples include:

Concentration Risk

A critical activity performed by a single vendor.

Governance Risk

Oversight responsibilities distributed across numerous functions.

Resource Risk

Large product portfolios supported by limited personnel.

Technology Risk

Dependence on a small number of critical systems.

Organisational Risk

Complex affiliate structures with unclear accountability.

The PSMF often reveals these risks more clearly than operational metrics alone.

PSMF Reviews from a QPPV Perspective

Many organisations conduct formal PSMF reviews.

Experienced QPPVs typically focus on different questions than document owners.

Instead of asking:

Is the document complete?

They ask:

Does the document still reflect reality?

Examples include:

• Are all critical vendors listed?
• Are organisational structures current?
• Have recent acquisitions been incorporated?
• Are governance descriptions still accurate?

This mindset often identifies issues that traditional document reviews miss.

The PSMF During Inspections

Inspectors frequently assess whether the QPPV understands the pharmacovigilance system.

The PSMF often becomes central to that assessment.

Common inspection questions may include:

• Explain your vendor oversight model.
• Explain your affiliate structure.
• Describe your governance arrangements.
• Describe your escalation pathways.

A QPPV who understands the PSMF usually answers these questions confidently.

A QPPV who has little familiarity with the document may struggle.

The PSMF During Organisational Change

Organisational change is often where the value of the PSMF becomes most apparent.

Examples include:

Acquisitions

New products and new processes enter the organisation.

Divestments

Responsibilities and systems change.

Vendor Transitions

Activities move between providers.

New QPPVs

Knowledge transfer becomes essential.

In each case the PSMF helps preserve understanding of how the pharmacovigilance system operates.

The PSMF as Institutional Memory

One of the most underappreciated functions of the PSMF is preserving organisational knowledge.

People leave.

Roles change.

Systems evolve.

The PSMF helps ensure that understanding of the pharmacovigilance system survives those transitions.

This is one reason mature organisations treat the PSMF as a strategic asset rather than a compliance document.

What Inspectors Expect from the QPPV

Inspectors generally do not expect the QPPV to memorise every annex.

They do expect the QPPV to understand:

• System structure
• Governance arrangements
• Major risks
• Critical vendors
• Escalation pathways
• Oversight activities

The PSMF should support that understanding.

If the document exists but does not help the QPPV perform oversight, its value is limited.

Characteristics of Strong QPPV Oversight

Strong oversight commonly includes:

Visibility

The QPPV understands the system.

Risk Awareness

The QPPV understands major risks.

Governance Engagement

The QPPV participates in governance activities.

Escalation

Significant issues reach the QPPV appropriately.

Continuous Review

The QPPV remains informed regarding system changes.

The PSMF supports each of these capabilities.

Common Oversight Weaknesses

Common deficiencies include:

• Limited understanding of vendors
• Poor visibility of affiliates
• Infrequent PSMF review
• Weak escalation pathways
• Lack of governance metrics

These weaknesses often become apparent during inspections.

The Future of QPPV Oversight

As pharmacovigilance systems become increasingly global and outsourced, oversight becomes more challenging.

Future trends are likely to include:

• Greater reliance on metrics
• Digital governance dashboards
• Automated inventories
• Real-time compliance monitoring

The PSMF will continue to play a central role because regulators will always require a structured description of how the system operates.

Key Takeaways

• The PSMF is one of the most important tools supporting QPPV oversight.
• Oversight differs fundamentally from operational management.
• The PSMF provides visibility regarding governance, accountability and risk.
• Vendor oversight, organisational complexity and system scope can all be assessed using the PSMF.
• Experienced QPPVs use the PSMF as a governance tool rather than simply a regulatory document.
• Inspectors frequently assess whether the QPPV understands the system described within the PSMF.
• A mature PSMF strengthens both oversight and inspection readiness.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
2. EMA Good Pharmacovigilance Practices (GVP) Module II – Pharmacovigilance System Master File.
3. EMA Good Pharmacovigilance Practices (GVP) Module III – Pharmacovigilance Inspections.
4. Regulation (EC) No 726/2004.
5. Directive 2001/83/EC.
6. Commission Implementing Regulation (EU) No 520/2012.
7. EMA Questions and Answers on Pharmacovigilance System Master Files.